Navigation Links
European Multidisciplinary Conference in Thoracic Oncology -- press program
Date:2/23/2011

The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.

The full text of the embargoed press releases/abstracts can be requested to the EMCTO Press Office at media@esmo.org. When the embargo lifts, the texts will be available in the ESMO Online Newsroom.

  1. Quick, easy test identifies aggressive type of lung cancer in never-smokers (embargo: 25 February 2011, 8:00 CET)
    Inexpensive and rapid test can effectively identify sub-group of never-smoking lung cancer patients whose tumors express molecule associated with increased risk of disease progression or recurrence.
    Author: Ping Yang, US

  2. Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer (embargo: 25 February 2011, 8:00 CET)
    Researchers identified a gene whose expression level strongly predicts how well and how long certain lung cancer patients will respond to treatment with erlotinib.
    Author: Rafael Rosell, Spain

  3. Bone drug zoledronic acid may help prevent spread of early lung cancer (embargo: 25 February 2011, 8:00 CET)
    Drug currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier state of treatment to prevent cancer from spreading.
    Author: Michela Quirino, italy

  4. Radio-guided surgery, a safe and simple way to remove potentially cancerous nodules in the lung (embargo: 26 February 2011, 8:00 CET)
    Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques.
    Author: Luca Bertolaccini, Italy

  5. Phase III trial: erlotinib as effective as chemo, with fewer side-effects, in patients whose disease progressed after first-line treatment (embargo: 26 February 2011, 8:00 CET)
    Targeted cancer drug erlotinib has comparable efficacy to chemotherapy and is better tolerated in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
    Author: Tudor Ciuleanu, Romania


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. IOF calls on European citizens to stand tall and speak out for their bones
2. IronKey Opens New European Office
3. European researchers harness unique properties of boron to develop new drugs and diagnostics
4. Vidaza receives positve opinion from European CHMP
5. The MDS foundation supports vidazas recommendation for European approval
6. European biodiversity and ecosystem scientists merge and gear up for long-term research
7. Overfishing threatens European bluefin tuna
8. European ancestry increases breast cancer risk among Latinas
9. IRB Barcelona to coordinate two European projects on biomedicine
10. Key to future medical breakthroughs is systems biology, say leading European scientists
11. Global warming linked to European viral epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):
(Date:7/26/2017)... , ... July 26, 2017 , ... ... Research Program at the National Institutes of Health (NIH), will be one of ... annual conference provides a platform for a multi-stakeholder discussion on the latest advancements ...
(Date:7/25/2017)... River Falls, Wisconsin (PRWEB) , ... July 25, 2017 , ... ... solutions for the food and beverage industry, offers Citri-Fi® 125. This natural citrus fiber ... used to thicken and extend real tomato in sauces, condiments and spreads. Today, more ...
(Date:7/24/2017)... ... July 24, 2017 , ... Charm Sciences, Inc. is pleased to ... National Conference on Interstate Milk Shipments (NCIMS) Laboratory Committee and Appendix N Committee as ... July 1, 2017. , The NCIMS voted at its annual meeting in April, 2015 ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... that the stock market news outlet had initiated coverage on Interpace Diagnostics. ... screens and identifies exposure, progression and risk analysis from specific cancers in ...
Breaking Biology Technology: